Today's pre-market stock movers: FDX, REV, BCS, KMX and more

• $Ballys (Delisted) (BALY.US)$ +6% (announces modified "Dutch auction" tender offer to purchase shares at $19.25-$22)

• $Ferguson (FERG.US)$ +3.4% (enters entered into a non-discretionary arrangement with its brokers J.P. Morgan Securities in continuation of its $2 billion share repurchase program)

• $Bausch Health (BHC.US)$ +3.3% (chairman resigns)

• $Sanofi (SNY.US)$ +3.2% (Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine)

• $NerdWallet (NRDS.US)$ +3.2% (to acquire On The Barrelhead for $120 mln)

• $Emergent BioSolutions (EBS.US)$ +3.1% (receives FDA Acceptance of BLA for AV7909 Anthrax vaccine candidate)

• $Intellia Therapeutics (NTLA.US)$ +2.4% (Intellia Therapeutics and Regeneron Pharmaceuticals (REGN) announce additional "positive" interim data from an ongoing Phase 1 study of their lead investigational in vivo genome editing candidate NTLA-2001)

• $FedEx (FDX.US)$ +2.4% (In reaction to earnings/guidance)

• $Biomarin Pharmaceutical (BMRN.US)$ +2.3% (confirms that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional marketing authorization for its investigational gene therapy valoctocogene roxaparvovec for adults with severe hemophilia A)

• $Castle Biosciences (CSTL.US)$ +2.2% (announces study findings that evaluated DecisionDx-UM)

• $Barclays (BCS.US)$ +2.2% (acquires Kensington Mortgage Company)

• $Takeda Pharmaceutical (TAK.US)$ +1.9% (to succeed to the rights and obligations relating to Plasma-Derived Therapies and all other businesses of Nihon through an absorption-type company split)

• $Novartis AG (NVS.US)$ +1.8% (receives positive CHMP opinion for Scemblix a novel treatment for adult patients with chronic myeloid leukemia)

• $Rocket Lab (RKLB.US)$ +1.7% (prepares to launch CAPSTONE to the Moon)

• $Datadog (DDOG.US)$ +1.6% (launches Datadog Audit Trail)

• $Primoris Services (PRIM.US)$ +1.6% (receives $260 mln solar project award)

• $GlaxoSmithKline (GSK.US)$ +1.1% (Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine)

• $Petroleo Brasileiro SA Petrobras (PBR.US)$ +1.1% (approved the sale of its total stake in the maritime concessions groups named Golfinho Cluster and Camarupim Cluster)

• $Aurora Cannabis (ACB.US)$ +4.2% (upgraded to Overweight from Neutral at Cantor Fitzgerald)

• $Becton Dickinson & Co (BDX.US)$ +1.2% (upgraded to Overweight from Equal Weight at Wells Fargo)

• $CalAmp (CAMP.US)$ -16.4% (In reaction to earnings/guidance)

• $LendingTree (TREE.US)$ -6% (lowers Q2 rev guidance due to challenging interest rate environment),

• $Revlon (REV.US)$ -5.7% (discloses that a portion of the proceeds of the initial borrowing under the DIP Term Loan Facility were used to repay in full and terminate the Foreign ABL Credit Agreement)

• $Cytokinetics (CYTK.US)$ -1.2% (FDA to hold Adcomm for omecamtiv mecarbil on Dec. 13 2022)

• $Smith & Wesson Brands (SWBI.US)$ -1.7% (also increases dividend)

• $CarMax (KMX.US)$ -0.8% (In reaction to earnings/guidance)

• $Novavax (NVAX.US)$ -0.9% (receives EUA in Taiwan for its Nuvaxovid COVID-19 vaccine for 18+)

• $Sarepta Therapeutics (SRPT.US)$ -0.5% (FDA places clinical hold on SRP-5051 for Duchenne muscular dystrophy)

• $Baxter International Inc (BAX.US)$ -1.7% (downgraded to Equal Weight from Overweight at Wells Fargo)

• $Ameriprise Financial (AMP.US)$ -1.1% (downgraded to Neutral from Buy at Goldman)